Question: is this a 2) strong advice, 1) weak advice 0) no advice?

In this large multinational study, treatment with SGLT-2i versus other glucose-lowering drugs was associated with a lower risk of HHF and death, suggesting that the benefits seen with empagliflozin in a randomized trial may be a class effect applicable to a broad population of patients with type 2 diabetes  mellitus in real-world practice.
user
This is no advice
assistant